https://www.businesswire.com/news/home/20231210164670/en/Independent-Data-Monitoring-Committee-Recommends-Continuing-the-Trial-Evaluating-Temelimab-in-Long-COVID-Without-Any-Modifications
Independent Data Monitoring Committee Recommends Continuing the Trial Evaluating Temelimab in Long...
Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neu...
data monitoring committee